| INTRODUCTION
Severe hypoglycaemia is a serious and potentially life-threatening complication of insulin therapy. 1, 2 Patients with type 1 diabetes (T1D) experience~2 symptomatic hypoglycaemic events (HEs)/week and 1 severe HE/year. 2, 3 Fear of hypoglycaemia is a major barrier to the achievement of glycaemic targets in people with T1D. 1, 4 Carbohydrate ingestion may not be possible in severe hypoglycaemia where the person may be unconscious or having a seizure. 5 In this scenario, caregivers can either inject glucagon or wait for professional help. The currently available glucagon kits require reconstitution prior to administration. 1, 6 Nasal glucagon (NG), a needle-free, single-use, compact, portable, drug-device combination consisting of 3 mg dry glucagon powder that does not require reconstitution, is currently under development as a rescue medication for severe hypoglycaemia. 1 NG (3 mg) produced a rapid increase in blood glucose (BG) levels and was non-inferior to intramuscular glucagon
(1 mg) in a previous study in adults with insulin-induced hypoglycaemia. 5 The aim of the present study was to evaluate the real-world effectiveness, tolerability and ease of use of NG (3 mg nasal glucagon; Eli Lilly and Company) in the treatment of moderate and severe HEs in adults with T1D. 
| MATERIALS AND METHODS

| RESULTS
Patient disposition and baseline characteristics are shown in Figure S1 and Table S1 , respectively. Out of 129 patients enrolled, 101 completed the study; 87 received ≥1 NG dose. The main safety analysis population included 74 patients (179 events); the efficacy analysis population included 69 patients (157 events).
| Efficacy results
A total of 66 patients (95.7%) in the efficacy analysis population awakened or achieved normality within 30 minutes after NG administration in at least 1 evaluable event whereas 64 patients (92.8%) awakened or achieved normality in all evaluable events ( Figure S2 ).
Six moderate, symptomatic HEs (3.8%) did not resolve within 30 minutes of NG administration. In 4 of these events, patients' BG levels were >3.9 mmol/L (70 mg/dL) within 30 minutes; however, they did not report return to normality because of headache and/or nasal irritation. In 2 events, BG levels increased by ≥1.1 mmol/L (20 mg/dL) and patients returned to normality between 30 and 45 minutes later (Table S2) .
Seven patients in the efficacy analysis population reported 12 severe HEs, with BG levels ranging from 1.6 to 3.3 mmol/L (29 to 60 mg/dL) at the time of NG administration. In all severe HEs, including those in patients who were unconscious or had convulsions, patients awakened or returned to normality within 15 minutes of NG administration (Table S3 ).
There were 7 events (including 2 severe events) in 6 patients in whom oral carbohydrates were used before treatment success criteria were met (Table S4 ).
| Safety results
Data on adverse events (AEs) were solicited through questionnaires.
In the main safety analysis population, 87.8% patients experienced ≥1 AE. The most common AE was nasal irritation, reported by 82.4%
of patients (Table S5) ; in more than half of these patients, it was short-lasting and resolved within 1 hour. One patient withdrew from the study because of local nasal AEs. Most AEs were of low to moderate severity. No serious drug-related AE was reported.
| Ease of use and caregiver satisfaction
In most HEs, caregivers reported that it was easy to understand the kit instructions (91% events) and administer NG (80.5% events). Caregivers were able to administer NG within 30 seconds in 70.4% of events and within 1 minute in 92.7% of events. Overall, in 94.4% of HEs, caregivers were satisfied with NG use (Figure 1 ). Caregivers expressed willingness to carry NG (97.7% events) and agreed that NG was less intimidating than injectable glucagon (100% events).
| DISCUSSION
In the present real-world study, we observed that 96.2% of HEs resolved within 30 minutes of NG administration. A previous randomized study in adults with T1D showed that 3-mg NG was noninferior to 1-mg intramuscular glucagon in treating insulin-induced hypoglycaemia in a hospital setting. 5 Another study in young people with T1D found that NG and injectable glucagon demonstrated similar glycaemic responses. 8 The results of the present study, together with previous research, suggest that NG shows promise as an effica- Hypoglycaemia has been associated with cardiac arrhythmias and increased risk of death in critically ill, hospitalized patients.
9,10
Recently, there has been increased awareness about the importance of clinically significant hypoglycaemia (identified by the International Hypoglycaemia Study Group as BG <3.0 mmol/L [54 mg/dL]) with its associated risk of potential harm. 11 Recent literature has also reported that hypoglycaemia with BG <2.8 mmol/L (50 mg/dL) is associated with increased mortality; therefore, this cutoff could be an objective, measurable criterion by which to detect dangerous hypoglycaemia in a broader group of patients at risk of severe hypoglycaemia. 12 In the present study, all patients who experienced moderate HEs had neuroglycopaenic symptoms and were at a risk of negative clinical outcomes; therefore, these moderate symptomatic events can be considered serious enough to represent surrogates for severe events.
Nausea and vomiting, well-known side effects of glucagon, were reported in 23% and 9.5% of patients, respectively. Local AEs such as transient nasal irritation, were commonly reported with NG; many of these were of mild to moderate severity. Although nasal irritation was perceived as severe by 16.2% patients, this should be seen in the context of the potential benefit of NG as a life-saving, rescue medication.
Caregivers reported that NG was easy to administer (80.5% events). They were able to administer the medication successfully within 30 seconds in the majority of cases (70.4% events) and were satisfied with NG use (94.4% events). Our findings are similar to those of a recent severe hypoglycaemia simulation study, 13 which compared the user-friendliness and success rate for administration of Abbreviations: HE, hypoglycaemic event; NG, nasal glucagon.
a Details regarding the 6 HEs in which patients did not return to normal status within 30 min are presented in Table S2 .
b Percentages based on the total number of events where "Time to awaken from severe event where patient was unconscious or had convulsions" was reported (n = 10).
c Percentages based on the total number of events where "Time to return to normal status from severe event where patient was conscious" was reported (n = 2).
d Percentages based on the total number of moderate events (n = 145).
e In this HE, the patient reported persistent headache, which prevented the patient from returning to normal status.
NG with injectable glucagon when administered to mannequins in a simulated severe hypoglycaemia situation. That study found that a higher percentage of people (caregivers and acquaintances) were able to administer NG as compared to injectable glucagon. Furthermore, the average time taken to administer NG was less than the time taken to administer injectable glucagon. 13 Injectable glucagon has been the treatment of choice for hypoglycaemia, and its efficacy is well established 1 ; however, injectable glucagon requires reconstitution and injection. In contrast, NG is needle-free and ready-to-use, and a single 3-mg dose can be used in both adult and paediatric patients independent of body weight. 14 Our data showed that the 3-mg NG drug-device combination was not only efficacious but also showed effectiveness in a real-world scenario. All patients with severe hypoglycaemia recovered within 15 minutes of NG administration, and all caregivers were able to use it successfully, confirming its effectiveness in the hands of the intended user.
A potential limitation of this pragmatic study is that it had a single arm; however, the protocol allowed the use of intramuscular glucagon, if needed. Additionally, there was a provision to call for emergency medical aid if the patient did not respond. This allowance to access emergency medical services in case of non-response served as an alternative rescue option, which was not required in any HE. Because it has already been shown that NG is non-inferior to injectable glucagon, 5 the design of the present study was appropriate to investigate its effectiveness in the real world.
This phase III, real-world study suggests that a single 3-mg dose of NG may be a viable and effective option in treating severe hypoglycaemia in adults with T1D. Approximately 70% of caregivers were able to administer NG within 30 seconds; >90% were able to administer it within 1 minute and no alternative external medical assistance was needed, confirming the effectiveness of NG in the hands of the final user. NG was found to be effective and reasonably well tolerated in adults with T1D.
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